{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:01:30Z","timestamp":1780041690915,"version":"3.53.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.critrevonc.2026.105334","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T08:20:08Z","timestamp":1775809208000},"page":"105334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Therapeutic sequencing and role of cabozantinib after immunotherapy in metastatic renal cell carcinoma"],"prefix":"10.1016","volume":"223","author":[{"given":"Martina","family":"Catalano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismaela Anna","family":"Vascotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Sthembari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pratesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Paulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinella Micol","family":"Mela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Pillozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5504-8237","authenticated-orcid":false,"given":"Giandomenico","family":"Roviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105334_bib1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejca.2020.09.030","article-title":"Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: results from the CABOREAL Early Access Program","volume":"142","author":"Albiges","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105334_bib2","article-title":"Towards a consensus on the management of metastatic renal cell carcinoma: insights from a European Delphi study","volume":"8","author":"Albiges","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105334_bib3","article-title":"CaboPoint: a phase 2 study of second-line cabozantinib after checkpoint inhibitor-based combination therapy in patients with metastatic renal cell carcinoma","author":"Albiges","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2026.105334_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01290","article-title":"Mechanisms of cancer resistance to immunotherapy","volume":"10","author":"Bai","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105334_bib5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.eururo.2024.10.019","article-title":"First and second-line treatments in metastatic renal cell carcinoma","volume":"87","author":"Barragan-Carrillo","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2026.105334_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1442888","article-title":"Tumor microenvironment and cancer metastasis: molecular mechanisms and therapeutic implications","volume":"15","author":"Biray Avci","year":"2024","journal-title":"Front. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105334_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102792","article-title":"Implications of bone metastasis on response to systemic therapy in patients with advanced renal cell carcinoma: a systematic literature review","volume":"129","author":"Brown","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105334_bib8","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105334_bib9","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105334_bib10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.bulcan.2017.03.013","article-title":"Cabozantinib: Mechanism of action, efficacy and indications","volume":"104","author":"Cochin","year":"2017","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105334_bib11","article-title":"Management of metastatic clear cell renal cell carcinoma: ASCO guideline","author":"Kimryn Rathmell","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105334_bib12","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12967-014-0294-y","article-title":"Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine","volume":"12","author":"Kwilas","year":"2014","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105334_bib13","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1177\/1078155219875509","article-title":"Cabozantinib use in metastatic renal cell carcinoma patients in clinical practice: evaluation of dosing patterns, tolerability, and outcomes compared to clinical trials","volume":"26","author":"McElwee","year":"2020","journal-title":"J. Oncol. Pharm. Pr."},{"key":"10.1016\/j.critrevonc.2026.105334_bib14","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105334_bib15","doi-asserted-by":"crossref","unstructured":"Motzer, R.J., Park, H., Mcdermott, R.S., Porta, C., Yick, D., Heng, C., Burotto, M., Iacovelli, R., Verzoni, E., Cutuli, H., Haanen, J., Su\u00e1rez, C., De Velasco, G., Valderrama, B.\u223c N.P., Westgeest, H.M., Yuan, S., Perini, R.F., Wang, D., Schmidinger, M., 2026. Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti-PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study.","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA417"},{"key":"10.1016\/j.critrevonc.2026.105334_bib16","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105334_bib17","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105334_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102141","article-title":"Real-world treatment sequencing and outcomes with cabozantinib after first-line immune checkpoint inhibitor-based combination therapy for patients with advanced renal cell carcinoma: CARINA study results","volume":"22","author":"Nathan","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105334_bib19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105334_bib20","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606","volume":"35","author":"Powles","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105334_bib21","doi-asserted-by":"crossref","first-page":"e945","DOI":"10.1016\/j.clgc.2018.03.014","article-title":"Safety and efficacy of cabozantinib in metastatic renal-cell carcinoma: real-world data from an italian managed access program","volume":"16","author":"Procopio","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105334_bib22","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105334_bib23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejcsup.2013.07.016","article-title":"Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors","volume":"11","author":"Schmidinger","year":"2013","journal-title":"Eur. J. Cancer Suppl."},{"key":"10.1016\/j.critrevonc.2026.105334_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.756225","article-title":"Immune evasion mechanism and AXL","volume":"11","author":"Son","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105334_bib25","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12943-023-01911-x","article-title":"Evolution of cell therapy for renal cell carcinoma","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105334_bib26","article-title":"AXL signaling in cancer: from molecular insights to targeted therapies","volume":"10","author":"Yadav","year":"2025","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:02:42Z","timestamp":1780038162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826002210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":26,"alternative-id":["S1040842826002210"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105334","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic sequencing and role of cabozantinib after immunotherapy in metastatic renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105334","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105334"}}